reported that patients with stage III/IV DLBCL had a higher frequency of double expression of MYC and BCL2 than those with stage I/II DLBCL (65.7% vs. 34.3%, p = 0.381).33 This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.